Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a and Olaparib in HER2-Expressing Malignancies
NCT04585958Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan and olaparib in solid tumor and ovarian cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum tolerated dose/recommended phase 2 dose up to 42 days and Incidence of adverse events. Started May 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecanolaparib
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT04585958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585958.